Open Access
Open access

Post-treatment With Irisin Attenuates Acute Kidney Injury in Sepsis Mice Through Anti-Ferroptosis via the SIRT1/Nrf2 Pathway

Qiongyue Zhang 1
Xin Yang 1
Meng Peng 1
Mi Sulin 2
Yanlin Wang 1
Xinyi Li 1
Xuemin Song 3
1
 
Department of Anesthesiology, China
2
 
Department of Cardiovascular Ultrasound, China
3
 
Research Centre of Anesthesiology and Critical Care Medicine, China
Publication typeJournal Article
Publication date2022-03-17
scimago Q1
wos Q1
SJR1.220
CiteScore8.9
Impact factor4.8
ISSN16639812
Pharmacology
Pharmacology (medical)
Abstract

Kidney is one of the most vulnerable organs in sepsis, resulting in sepsis-associated acute kidney injury (SA-AKI), which brings about not only morbidity but also mortality of sepsis. Ferroptosis is a new kind of death type of cells elicited by iron-dependent lipid peroxidation, which participates in pathogenesis of sepsis. The aim of this study was to verify the occurrence of ferroptosis in the SA-AKI pathogenesis and demonstrate that post-treatment with irisin could restrain ferroptosis and alleviate SA-AKI via activating the SIRT1/Nrf2 signaling pathway. We established a SA-AKI model by cecal ligation and puncture (CLP) operation and an in vitro model in LPS-induced HK2 cells, respectively. Our result exhibited that irisin inhibited the level of ferroptosis and ameliorated kidney injury in CLP mice, as evidenced by reducing the ROS production, iron content, and MDA level and increasing the GSH level, as well as the alteration of ferroptosis-related protein (GPX4 and ACSL4) expressions in renal, which was consistent with the ferroptosis inhibitor ferrostatin-1 (Fer-1). Additionally, we consistently observed that irisin inhibited ROS accumulation, iron production, and ameliorated mitochondrial dysfunction in LPS-stimulated HK-2 cells. Furthermore, our result also revealed that irisin could activate SIRT1/Nrf2 signaling pathways both in vivo and vitro. However, the beneficial effects of irisin were weakened by EX527 (an inhibitor of SIRT1) in vivo and by SIRT1 siRNA in vitro. In conclusion, irisin could protect against SA-AKI through ferroptotic resistance via activating the SIRT1/Nrf2 signaling pathway.

Found 
Found 

Top-30

Journals

2
4
6
8
10
International Immunopharmacology
10 publications, 7.69%
Frontiers in Pharmacology
4 publications, 3.08%
Life Sciences
4 publications, 3.08%
Frontiers in Immunology
4 publications, 3.08%
Naunyn-Schmiedeberg's Archives of Pharmacology
4 publications, 3.08%
Journal of Advanced Research
3 publications, 2.31%
Biomedicine and Pharmacotherapy
3 publications, 2.31%
Frontiers in Medicine
3 publications, 2.31%
Drug Development Research
3 publications, 2.31%
Brain Research Bulletin
2 publications, 1.54%
Antioxidants
2 publications, 1.54%
Biomolecules
2 publications, 1.54%
Cell Death Discovery
2 publications, 1.54%
Biomedicines
2 publications, 1.54%
eLife
2 publications, 1.54%
Kaohsiung Journal of Medical Sciences
2 publications, 1.54%
Phytomedicine
2 publications, 1.54%
Phytotherapy Research
2 publications, 1.54%
Journal of Agricultural and Food Chemistry
1 publication, 0.77%
Frontiers in Aging Neuroscience
1 publication, 0.77%
Frontiers in Endocrinology
1 publication, 0.77%
Pharmaceuticals
1 publication, 0.77%
Food and Chemical Toxicology
1 publication, 0.77%
Inflammation Research
1 publication, 0.77%
Journal of Bioenergetics and Biomembranes
1 publication, 0.77%
Human and Experimental Toxicology
1 publication, 0.77%
European Journal of Medicinal Chemistry
1 publication, 0.77%
Free Radical Biology and Medicine
1 publication, 0.77%
Open Medicine (Poland)
1 publication, 0.77%
Oxidative Medicine and Cellular Longevity
1 publication, 0.77%
2
4
6
8
10

Publishers

5
10
15
20
25
30
35
40
45
Elsevier
42 publications, 32.31%
Springer Nature
24 publications, 18.46%
Frontiers Media S.A.
16 publications, 12.31%
Wiley
12 publications, 9.23%
MDPI
10 publications, 7.69%
Taylor & Francis
7 publications, 5.38%
American Chemical Society (ACS)
2 publications, 1.54%
Walter de Gruyter
2 publications, 1.54%
S. Karger AG
2 publications, 1.54%
Spandidos Publications
2 publications, 1.54%
eLife Sciences Publications
2 publications, 1.54%
SAGE
1 publication, 0.77%
Hindawi Limited
1 publication, 0.77%
Mary Ann Liebert
1 publication, 0.77%
Royal Society of Chemistry (RSC)
1 publication, 0.77%
Pharmaceutical Society of Japan
1 publication, 0.77%
Scientific Scholar
1 publication, 0.77%
Bentham Science Publishers Ltd.
1 publication, 0.77%
IMR Press
1 publication, 0.77%
American Society for Microbiology
1 publication, 0.77%
5
10
15
20
25
30
35
40
45
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
130
Share
Cite this
GOST |
Cite this
GOST Copy
Zhang Q. et al. Post-treatment With Irisin Attenuates Acute Kidney Injury in Sepsis Mice Through Anti-Ferroptosis via the SIRT1/Nrf2 Pathway // Frontiers in Pharmacology. 2022. Vol. 13.
GOST all authors (up to 50) Copy
Zhang Q., Xin Yang, Meng Peng, Sulin M., Wang Y., Xinyi Li, Song X. Post-treatment With Irisin Attenuates Acute Kidney Injury in Sepsis Mice Through Anti-Ferroptosis via the SIRT1/Nrf2 Pathway // Frontiers in Pharmacology. 2022. Vol. 13.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3389/fphar.2022.857067
UR - https://doi.org/10.3389/fphar.2022.857067
TI - Post-treatment With Irisin Attenuates Acute Kidney Injury in Sepsis Mice Through Anti-Ferroptosis via the SIRT1/Nrf2 Pathway
T2 - Frontiers in Pharmacology
AU - Zhang, Qiongyue
AU - Xin Yang
AU - Meng Peng
AU - Sulin, Mi
AU - Wang, Yanlin
AU - Xinyi Li
AU - Song, Xuemin
PY - 2022
DA - 2022/03/17
PB - Frontiers Media S.A.
VL - 13
PMID - 35370723
SN - 1663-9812
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Zhang,
author = {Qiongyue Zhang and Xin Yang and Meng Peng and Mi Sulin and Yanlin Wang and Xinyi Li and Xuemin Song},
title = {Post-treatment With Irisin Attenuates Acute Kidney Injury in Sepsis Mice Through Anti-Ferroptosis via the SIRT1/Nrf2 Pathway},
journal = {Frontiers in Pharmacology},
year = {2022},
volume = {13},
publisher = {Frontiers Media S.A.},
month = {mar},
url = {https://doi.org/10.3389/fphar.2022.857067},
doi = {10.3389/fphar.2022.857067}
}